AstraZeneca expects revenue to grow at a mid-to-high single-digit rate and underlying earnings to grow at a low-double-digit rate at constant exchange rates in 2026.[1][3] Growth will be driven mainly by strong demand for oncology drugs, which are growing at a double-digit rate.[1][3] In 2025, sales increased by 8% and profits by 11%, which met the company's forecasts.[1][3] Sales of oncology drugs rose 20% to $7.03 billion in the fourth quarter of 2025, while sales of cardiovascular drugs fell 6% to $3.05 billion.[3] The company plans to reach $80 billion in annual sales by 2030.[1][2][3] Massive investments in the US and China contribute to long-term growth, where it accounts for approximately 40% of US revenue.[1][2][3] It has 11 manufacturing plants in the US and will invest 3.5 billion USD there by the end of next year.[2] In the first quarter of 2025, it made a profit of $2.92 billion, up 30% from last year, thanks to sales of cancer drugs.[2]